SCHEMBL863630

SCHEMBL863630

c1ccc(-c2nnc3ccc(-c4ccc5[nH]ccc5c4)nn23)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.52
BRD4 O60885 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA2B P29275 1/20 0.48
ADORA1 P30542 1/20 0.48
CREBBP Q92793 1/20 0.48
KDM4E B2RXH2 2/20 0.45
HSD17B10 Q99714 2/20 0.45
HPGD P15428 1/20 0.45
DYRK3 O43781 3/20 0.44
CCNT1 O60563 3/20 0.44
CDK9 P50750 3/20 0.44
CDK5 Q00535 3/20 0.44
DYRK1A Q13627 3/20 0.44
CDK5R1 Q15078 3/20 0.44
DYRK2 Q92630 3/20 0.44
DYRK1B Q9Y463 3/20 0.44
CCNA2 P20248 2/20 0.44
CDK2 P24941 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863714 0.86 DYRK3 (0.46) NPC1KDM4EHSD17B10DYRK3CCNT1
SCHEMBL864043 0.84 MET (0.43) NPC1BRD4DYRK3CCNT1CDK9
SCHEMBL863333 0.79 GUSB (0.43) BRD4HSD17B10DYRK3CCNT1CDK9
SCHEMBL2646931 0.79 KDM4E (0.67) BRD4ADORA3ADORA2AADORA2BADORA1
SCHEMBL863987 0.73 MET (0.46) BRD4ADORA3ADORA2AADORA2BADORA1
SCHEMBL16009418 0.73 DYRK3 (0.77) DYRK3CCNT1CDK9CDK5DYRK1A
SCHEMBL446619 0.71 NPC1 (1.00) NPC1DYRK3CDK5DYRK1ACDK5R1
SCHEMBL30587350 0.71 NPC1 (1.00) NPC1DYRK3CDK5DYRK1ACDK5R1
SCHEMBL2961538 0.71 DYRK3 (0.56) NPC1DYRK3CCNT1CDK9CDK5
SCHEMBL25439912 0.70 NPC1 (0.71) NPC1BRD4ADORA2AADORA1GLO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865719-B2 Substituted heterocycles and their use as allosteric modulators of nicotinic and GABAA receptors THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-10-21 US disclosed
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077816-A1 SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINIC AND GABAA RECEPTORS CHRNA7, CHRNA5, CHRNA1 NPC1 2210/4885BRD4 738/4885ADORA3 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.